← Leaderboards
Priscilla A. Furth
University Of Maryland Baltimore
$6,008,619
Attributed
$6,008,619
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $655.3K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,008,619 · 6
By mechanism
R01$5,075,592 · 2
UH3$434,533 · 1
R56$193,854 · 1
R29$154,866 · 1
UH2$149,774 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResponseMammary GlandBreastMouse ModelHormonalIntraductal HyperplasiaNoninfiltrating Intraductal CarcinomaMammary NeoplasmsTumor ProgressionIn VivoResistanceEstrogen Receptor AlphaWomanMalignant Breast NeoplasmTissuesMolecularTamoxifenMalignant - DescriptorResearch StudyProgramsBiological MarkersTp53 GeneGene Expression
Grant awards (31)
Impact of aging on progression and prevention of mammary preneoplasia and cancer$150,000
UH3 · FY2020 · CA · contact PI
Impact of aging on progression and prevention of mammary preneoplasia and cancer$146,255
UH3 · FY2019 · CA · contact PI
Progression and regression of mammary preneoplasia$311,000
R01 · FY2018 · CA · contact PI
Impact of aging on progression and prevention of mammary preneoplasia and cancer$138,278
UH3 · FY2018 · CA · contact PI
Progression and regression of mammary preneoplasia$311,000
R01 · FY2017 · CA · contact PI
Impact of aging on progression and prevention of mammary preneoplasia and cancer$75,386
UH2 · FY2017 · CA · contact PI
Progression and regression of mammary preneoplasia$311,000
R01 · FY2016 · CA · contact PI
Impact of aging on progression and prevention of mammary preneoplasia and cancer$74,388
UH2 · FY2016 · CA · contact PI
Progression and regression of mammary preneoplasia$311,000
R01 · FY2015 · CA · contact PI
Progression and regression of mammary preneoplasia$311,000
R01 · FY2014 · CA · contact PI
Mechanisms Regulating Reversal of Premalignancy and Threapuetic Sensitivity$193,854
R56 · FY2012 · DE · contact PI
Progression and regression of mammary preneoplasia$271,505
R01 · FY2009 · CA · contact PI
Mechanisms Regulating Reversal of Malignancy$197,947
R01 · FY2009 · CA · contact PI
Mechanisms Regulating Reversal of Malignancy$96,935
R01 · FY2009 · CA · contact PI
Progression and regression of mammary preneoplasia$88,950
R01 · FY2009 · CA · contact PI
Progression and regression of mammary preneoplasia$271,505
R01 · FY2008 · CA · contact PI
Mechanisms Regulating Reversal of Malignancy$197,947
R01 · FY2008 · CA · contact PI
Progression and regression of mammary preneoplasia$67,072
R01 · FY2008 · CA · contact PI
Progression and regression of mammary preneoplasia$271,505
R01 · FY2007 · CA · contact PI
Mechanisms Regulating Reversal of Malignancy$199,529
R01 · FY2007 · CA · contact PI
Progression and regression of mammary preneoplasia$279,615
R01 · FY2006 · CA · contact PI
Mechanisms Regulating Reversal of Malignancy$216,030
R01 · FY2006 · CA · contact PI
Progression and regression of mammary preneoplasia$31,040
R01 · FY2006 · CA · contact PI
Progression and regression of mammary preneoplasia$286,344
R01 · FY2005 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$209,520
R01 · FY2005 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$209,520
R01 · FY2004 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$209,520
R01 · FY2003 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$209,520
R01 · FY2002 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$141,612
R01 · FY2001 · CA
MECHANISMS REGULATING REVERSAL OF PREMALIGNANCY$64,976
R01 · FY2001 · CA
BCL-2 GENE FAMILY, APOPTOSIS RESISTANCE AND BREAST CANCE$154,866
R29 · FY2000 · CA